Second-Generation Antiepileptic Drugs' Impact on Balance: A Meta-analysis

Sirven, Joseph I.; Terry D. Fwe; Wingerchuk, Dean M.; Drazkowski, Joseph F.
January 2007
Mayo Clinic Proceedings;Jan2007, Vol. 82 Issue 1, p40
Academic Journal
OBJECTIVE: To systematically review available evidence regarding whether second-generation antiepileptic drugs (AED5) contribute to the risk of balance disorders. METHODS: We systematically evaluated data from randomized controlled trials that compared adjunctive therapy with a second-generation AED (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, or zonisamide) vs placebo for partial epilepsy and that reported dose-specific rates of ataxia or imbalance for each group. Random-effects meta-analysis was used to pool ratios (risk ratio [RR]) and associated 95% confidence intervals to determine whether there was evidence of an overall AED class effect or a dose-response effect and whether there were differences between individual AEDs. RESULTS: Sixteen studies met inclusion criteria, representing 4279 individuals randomized to a second-generation AED and 1830 patients to placebo. Pooled analyses of all AEDs demonstrated that they increase imbalance risk at any dose (RR, 2.73; 95% confidence Interval, 2.07-3.61) and at lowest dose (RR, 1.76; 95% confidence Interval, 1.26-2.46). The highest dose analysis showed heterogeneity; evaluation of individual AEDs revealed that oxcarbamazepine and topiramate increased imbalance risk at all doses, whereas gabapentin and levetiracetam did not increase imbalance risk at any dose. A dose-response effect was observed for most AEDs. CONCLUSION: Second-generation AEDs at standard dosages, except for gabapentin and levetiracetam, increase the imbalance risk, and evidence exists for a dose-response effect. The mechanisms, risk factors, and consequences of this risk for individual AEDs warrant further study.


Related Articles

  • Fish oil (n-3 fatty acids) in drug resistant epilepsy: a randomised placebo-controlled crossover study. DeGiorgio, Christopher M.; Miller, Patrick R.; Harper, Ronald; Gornbein, Jeffrey; Schrader, Lara; Soss, Jason; Meymandi, Sheba // Journal of Neurology, Neurosurgery & Psychiatry;Jan2015, Vol. 86 Issue 1, p65 

    Background n-3 fatty acids inhibit neuronal excitability and reduce seizures in animal models. High-dose fish oil has been explored in two randomised trials in drug resistant epilepsy with negative results. We performed a phase II randomised controlled crossover trial of lowdose and high-dose...

  • Greater Response to Placebo in Children Than in Adults: A Systematic Review and Meta-Analysis in Drug-Resistant Partial Epilepsy. Rheims, Sylvain; Cucherat, Michel; Arzimanoglou, Alexis; Ryvlin, Philippe // PLoS Medicine;Aug2008, Vol. 5 Issue 8, pe166 

    In a systematic review of antiepileptic drugs, Philippe Ryvlin and colleagues find that children with drug-resistant partial epilepsy enrolled in trials seem to have a greater response to placebo than adults enrolled in such trials.

  • Testosterone and Cardiovascular Risk in Men: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Haddad, Rudy M.; Kennedy, Cassie C.; Caples, Sean M.; Tracz, Michal J.; Boloña, Enrique R.; Sideras, Kostandinos; Uraga, Maria V.; Erwin, Patricia J.; Montori, Victor M. // Mayo Clinic Proceedings;Jan2007, Vol. 82 Issue 1, p29 

    OBJECTIVE: To conduct a systematic review and meta-analysis of randomized trials that assessed the effect of testosterone use on cardiovascular events and risk factors in men with different degrees of androgen deficiency. METHODS: Librarian-designed search strategies were used to search the...

  • Greater Response to Placebo in Children Than in Adults: A Systematic Review and Meta-Analysis in Drug-Resistant Partial Epilepsy. Rheims, Sylvain; Cucherat, Michel; Arzimanoglou, Alexis; Ryvlin, Philippe // PLoS Clinical Trials;Aug2008, Vol. 5 Issue 8, p1223 

    Background Despite guidelines establishing the need to perform comprehensive paediatric drug development programs, pivotal trials in children with epilepsy have been completed mostly in Phase IV as a postapproval replication of adult data. However, it has been shown that the treatment response...

  • Epilepsy Drug Linked to Heart Attack Risk. Gerson, Charlotte // Gerson Healing Newsletter;Jul/Aug2007, Vol. 22 Issue 4, p6 

    The article focuses on the probable association of heart attack risks and antiepileptic drugs. According to the author, a doctor from Vicenza, Italy has been researching one aspect of drug therapy for epilepsy and has made the discovery that drugs like Phenobarbital appear to raise the...

  • Treatment options for poststroke seizures extrapolated from those for epilepsy. Adis International Limited // Drugs & Therapy Perspectives;Jul2005, Vol. 21 Issue 7, p7 

    Looks at some treatment options for poststroke seizures. Cumulative probabilities of developing seizures by 5 years after stroke, according to community-based, prospective cohort studies; Risk factors for recurrent seizures; Variety of antiepileptic drugs.

  • Effect of Melatonin on Seizure Frequency in Intractable Epilepsy: A Pilot Study. Goldberg-Stern, Hadassa; Oren, Heftsiba; Peled, Nir; Garty, Ben-Zion // Journal of Child Neurology;Dec2012, Vol. 27 Issue 12, p1524 

    Melatonin is effective for treating sleep–wake cycle disturbances and has been reported occasionally to decrease epileptic seizure frequency, with no long-term side effects. In this pilot study, the investigators examined the effect of melatonin on seizures, sleep quality, and behavior in...

  • Lamotrigine as an Effective Treatment for Behavioral Disorders. Rita Moretti; Paola Torre; Cristina Vilotti; Rodolfo M. Antonello // Letters in Drug Design & Discovery;Aug2007, Vol. 4 Issue 6, p446 

    Lamotrigine is thought to act at voltage-sensitive sodium channels to stabilize neuronal membranes and inhibit the release of excitatory amino acid neurotransmitters (e.g. glutamate, aspartate) that are thought to play a role in the generation and spread of epileptic seizures. In...

  • Lacosamide: What Can Be Expected from the Next New Antiepileptic Drug? Abou-Khalil, Bassel W. // Epilepsy Currents;Sep/Oct2009, Vol. 9 Issue 5, p133 

    PURPOSE: To evaluate the efficacy and safety of lacosamide (200 and 400 mg/day) when added to one to three concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial-onset seizures. METHODS: This multicenter, double-blind, placebo-controlled trial randomized patients (age...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics